BIOM Pharmaceutical Corporation Granted European Patent for LiveBIOM(TM) Microbiome Technology, Strengthening Position as Pioneer in Microbiome Therapeutics
March 15, 2024 at 06:01 am EDT
Share
SARASOTA, FL. - - BIOM Pharmaceutical Corporation (BIOM), a clinical-stage biopharmaceutical company focused on microbiome-based live bacterial therapeutics for the treatment of neurodevelopmental diseases, cancers, and other chronic diseases, announced that the European Patent Office has granted European Patent No. EP3490573 for LiveBIOM(TM) Microbiome Technology. This patent covers devices, systems, processes, and formulations for microbiome-modulating therapeutics. The newly granted European patent strengthens BIOM's patent estate, adding to its four issued US patents and establishing BIOM as a pioneer in the production of designer microbiome for various indications. The company has also filed various composition-of-matter and method-of-manufacturing formulations from the LiveBIOM(TM) platform technology targeted toward various disease conditions.
Bobban Subhadra PhD, BIOM's Chief Scientific Officer, commented, "LiveBIOM(TM) technology is a novel way to produce designer live bacterial therapeutics. As more studies focus on the role of the gut microbiome on human health, we need more than fecal transplant. That is why we created LiveBIOM(TM) technology. Expanding and protecting our intellectual property portfolio, including this new European patent, is a key catalyst for our growth plans."
About BIOM Pharmaceuticals:
BIOM Pharmaceutical is dedicated to extending healthy years to the human lifespan by regulating the human microbiome through probiotics. The company is a pioneer in microbiome technology with five issued US Patents and has developed LiveBIOM(TM) Technology to create humanized designer microbiome with applications in human health and disease, including immune regulation, cardiometabolic health, vaginal health, and neurodegeneration. BIOM has developed True-To-Label nutritional supplements and has four consumer brands with twenty-three products in the market: BIOM Probiotics® Total Gut Health products, VagiBiom® Feminine Care Products, Longiva® Antiaging and Longevity products, and LeanBiom® metabolic weight maintenance products.
For more information, please visit www.biompharma.com.
TM Technology, Inc. is a Taiwan-based company principally engaged in the research, development, manufacture and sales of integrated circuit (IC) chips and related components. The Company is also engaged in the provision of related technology and consultancy services. The Companyâs principal products include the optical communication ICs, light emitting diode (LED) ICs and flash memory controller ICs, such as fiber to the home (FTTH) integrated ICs and LED driving ICs. The Company mainly operates through two business segments: the TM Technology, Inc. segment and other operations segment. The Company distributes its products in domestic market and overseas markets, including the Mainland China and the rest regions of Asia.
BIOM Pharmaceutical Corporation Granted European Patent for LiveBIOM(TM) Microbiome Technology, Strengthening Position as Pioneer in Microbiome Therapeutics
TM TECHNOLOGY, INC. 
